Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · IEX Real-Time Price · USD
27.55
-0.69 (-2.44%)
At close: Jul 2, 2024, 4:00 PM
26.97
-0.58 (-2.11%)
After-hours: Jul 2, 2024, 6:28 PM EDT
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for TARS stock have an average target of 50.83, with a low estimate of 30 and a high estimate of 61. The average target predicts an increase of 84.50% from the current stock price of 27.55.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 13, 2024.
Analyst Ratings
The average analyst rating for TARS stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
Buy | 1 | 2 | 2 | 2 | 2 | 2 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $57 → $61 | Strong Buy | Maintains | $57 → $61 | +121.42% | May 13, 2024 |
Barclays | Barclays | Buy Maintains $50 → $60 | Buy | Maintains | $50 → $60 | +117.79% | May 10, 2024 |
Oppenheimer | Oppenheimer | Buy Maintains $59 → $61 | Buy | Maintains | $59 → $61 | +121.42% | May 9, 2024 |
Jefferies | Jefferies | Strong Buy Maintains $30 → $44 | Strong Buy | Maintains | $30 → $44 | +59.71% | Mar 6, 2024 |
Goldman Sachs | Goldman Sachs | Hold Maintains $19 → $30 | Hold | Maintains | $19 → $30 | +8.89% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
145.44M
from 17.45M
Increased by 733.61%
Revenue Next Year
265.83M
from 145.44M
Increased by 82.78%
EPS This Year
-3.77
from -4.62
EPS Next Year
-1.92
from -3.77
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 164.1M | 340.0M | 567.0M | 693.0M | 819.0M |
Avg | 145.4M | 265.8M | 445.4M | 637.8M | 755.4M |
Low | 121.5M | 202.9M | 320.5M | 578.7M | 687.1M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 840.8% | 133.8% | 113.3% | 55.6% | 28.4% |
Avg | 733.6% | 82.8% | 67.5% | 43.2% | 18.4% |
Low | 596.5% | 39.5% | 20.6% | 29.9% | 7.7% |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -2.98 | -1.21 | 4.42 |
Avg | -3.77 | -1.92 | 1.64 |
Low | -3.96 | -3.19 | -1.59 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.